Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

about

Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection.

P2860

Q40115808-9503300F-FE52-45E7-84F3-888B52271D42

P2860

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

Item

http://www.wikidata.org/entity/Q26852672

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@ast

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@en

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@nl

type

Item

label

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@ast

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@en

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@nl

prefLabel

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@ast

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@en

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@nl

P1476

Profile of PEGylated interfero ...... g-remitting multiple sclerosis

@en

P2860

Immunomodulatory activity of interferon-beta

Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.

Thrombotic microangiopathy associated with interferon beta

Assessing changes in relapse rates in multiple sclerosis.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

P304

759-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S69123

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eleonora Cocco

Maria Giovanna Marrosu

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26056458

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

multiple sclerosis

P932

4431469

http://www.w3.org/2001/XMLSchema#string

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

about

P2860

P2860

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932